REVOLUTION MEDICINES INC. - COMMON STOCK

Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023

06 4 2023 07:00:54 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

07 3 2023 16:02:17 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

02 3 2023 21:15:55 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Commencement of Public Offering of Common Stock

01 3 2023 16:17:35 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

27 2 2023 16:05:07 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

21 2 2023 16:05:16 提供 Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

02 2 2023 07:00:12 提供 Nasdaq GlobeNewswire

Revolution Medicines to Present at 41st Annual J.P. Morgan Healthcare Conference

03 1 2023 07:00:01 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Publication Describing Design and Synthesis of RMC-5552, a First-in-Class, Bi-Steric mTORC1-Selective Inhibitor

19 12 2022 07:00:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi’s Termination of SHP2 Inhibitor Development and Commercialization Collaboration

07 12 2022 16:05:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

09 11 2022 16:05:01 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate Progress

07 11 2022 16:05:02 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

01 11 2022 16:05:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

22 9 2022 07:00:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

01 9 2022 16:05:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Participate in Upcoming Investor Conferences

31 8 2022 16:05:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

09 8 2022 16:02:00 提供 Nasdaq GlobeNewswire

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

28 7 2022 16:02:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

22 7 2022 16:02:00 提供 Nasdaq GlobeNewswire

Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock

19 7 2022 22:41:52 提供 Nasdaq GlobeNewswire